Finally, the GFI1-36N variant depresses the HOXA9 expression by altering the epigenetic histone modification, which is consistent with the observation of frequently elevated HOXA9 expression levels in AML patients carrying the variant [64]. This evidence concerns the gene GFI1 and acute myeloid leukemia.